Keymed Biosciences, Inc. (2162) Stock Statistics & Valuation Metrics

Keymed Biosciences, Inc. has a market cap or net worth of HK$12.51B. The enterprise value is HK$11.12B.

Keymed Biosciences, Inc. has 279,735,570 shares outstanding. The number of shares has decreased by -2.65% in one year.

Keymed Biosciences, Inc.’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -17.86%.

The current PE Ratio of Keymed Biosciences, Inc. is -14.75. Keymed Biosciences, Inc.’s PEG ratio is -0.65.

In the last 12 months, Keymed Biosciences, Inc. had revenue of 428.12M and earned -515.24M in profits. Earnings per share was -1.97.

In the last 12 months, operating cash flow was -365.92M and capital expenditures -107.43M, giving a free cash flow of -473.35M billion.

Keymed Biosciences, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Keymed Biosciences, Inc. upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.

Keymed Biosciences, Inc. as a current ratio of 3.30, with Debt / Equity ratio of 30.44%

In the past 12 months, Keymed Biosciences, Inc. has paid 6.26M in taxes.

Keymed Biosciences, Inc. EV to EBITDA ratio is -13.82, with an EV/FCF ratio of 0.00.

Keymed Biosciences, Inc. has HK$2.16B in cash and marketable securities with ¥753.24M in debt, giving a net cash position of -HK$1.40B billion.

Gross margin is 97.15%, with operating margin of -144.37%, and net profit margin of -120.35%.

The average price target for Keymed Biosciences, Inc. is HK$60.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy